dilluns, 29 de gener del 2018

FDA to review Theravance’s application for once-daily COPD med

Mylan, TheravanceThe FDA has accepted Theravance Biopharma‘s (NSDQ:TBPH)  marketing application for revefenacin, an inhaled long-acting muscarinic antagonist designed to treat chronic obstructive pulmonary disease.

The FDA is slated to make a decision about the once-daily treatment by Nov. 13.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA to review Theravance’s application for once-daily COPD med appeared first on MassDevice.



from MassDevice http://ift.tt/2GrsZXX

Cap comentari:

Publica un comentari a l'entrada